Licensing deal: Sun pays $80 million to Merck

Merck is all set to license its experimental psoriasis drug – Tildrakizumab, to Indian pharma giant Sun Pharmaceuticals


According to the deal, Sun will pay an upfront payment of $80 million to Merck and will hold the right to market the drug worldwide.

The drug is currently said to be evaluated in Phase III registration trials for the treatment of chronic plaque psoriasis, a skin ailment.

Merck in a statement said that Sun would fund all the clinical development and regulatory activities relating to the drug.

Sun pharma explained that this collaboration is part of its strategy towards building a pipeline of dermatology products.

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

Union Budget

Has Union budget 2017 addressed all requirements of healthcare industry?

Send this article by email